Bruce Sachais, MD, PhD

Bruce Sachais.jpg
Title

Executive Medical Director
Head, Laboratory of Platelet Research
Associate Member, Lindsley F. Kimball Research Institute

Research Area

The Platelet Research Laboratory is interested in the pathobiology of platelets and platelet molecules.  We are currently focused on improved diagnosis and novel therapeutics for heparin induced thrombocytopenia/thrombosis (HITT).  We have recently published on  novel assays which may improve the precision and accuracy for diagnosis HITT.  Have also published on novel small molecules that interfere with the formation of heparin:PF4 complexes, which we call PF4 Antagonists (POF4As).  We are actively working to improve the potency and pharmacology of PF4As towards the development of PF4As as a therapeutic option for the treatment and/or prevention of HIT.  We are also interested in the pathgobiology of HIT as well as other platelet disorders.

Contact Information

Email: BSachais@nybc.org
Phone: +1 (212) 699-5154

Laboratory Personnel

  • Mandayam Nandan, MS (Laboratory Manager)

Funding Support

  • NIH R42 HL123126  PI: Sachais 09/2016 - 08/2018 "Small Molecule Antagonists of PF4 for the treatment and prevention of HIT, Phase II"
  • NIH P01 HL110860  PI:  Poncz  09/2012 - 08/2017 "Pathogenesis and Management of Heparin-induced Thrombocytopenia

Education and Training

Doctoral Training
M.D. Washington University
Ph.D. Washington University (Neuroscience)

Postdoctoral Training
Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine
Certificate in Patient Oriented Research, University of Pennsylvani

Selected Publications

Sachais, B.S., Rux. A.H, Cines, D.B., Yarovoi, S.V., Garner, L.I., Watson S.P., Hinds, J.L., Rux,J.J.: Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood 119(25): 5955-5962, June 2012 Notes: Plenary Paper. Inside Blood Accompanying.

Sachais, B.S., Litvinov, R.I., Yarovoi, S.V., Rauova, L., Hinds, J.L., Rux, A.H., Arepally, G.M., Poncz, M., Cuker, A., Weisel, J.W., and Cines, D.B.: Dynamic antibody binding properties in the pathogenesis of HIT. Blood 120: 1137-1142, August 2012 Notes: PMID: 22577175 (Editorial Accompanying).

Cuker A.,Rux A.H., Hinds J.L., Dela Cruz M., Yarovoi S.V., Brown I.A., Yang W., Konkle B.A., Arepally G.M., Watson S.P., Cines D.B., Sachais, B.S.: Novel diagnostic assays for heparin-induced thrombocytopenia. BLOOD 121: 3727-3732, May (Feb Ahead of print) 2013.

Litvinov, R.I., Yarovoi, S.V., Rauova, L., Barsegov, V., Sachais, B.S., Rux, A.H., Hinds, J.L., Arepally, G.M., Cines, D.B., Weisel, J.W.: Distinct Specificity and Single-molecule Kinetics Characterize the Interaction of Pathogenic and Non-pathogenic Antibodies against Platelet Factor 4-Heparin Complexes with Platelet Factor 4. Journal of Biological Chemistry 288(46): 33060-70, 2013.

Farooqi, M.S., Lai, Y., Lancaster, E., Schmitt, S.E., Sachais, B.S.: Therapeutic Plasma Exchange and Immunosuppressive Therapy in a Patient with Anti-GAD Antibody-Related Epilepsy: Quantification of the Antibody Response. Journal of Clinical Apheresis 30(1), 2014 Notes: Published online June 2014.

Price, T.H., Boeckh, M., Harrisonm R.W., McCullough, J., Ness, P.M. Strauss, R.G., Nichols, W.G., Hamza, T.H., Cushing, M.M., King, K.E., Young, J.H., Williams, E., McFarland, J., hakrabarty, J.H., Sloan, S.R., , D., Parekh, S., Sachais, B.S., Kiss, J.E., Assmann, S.F.: Efficacy of transfusion with granulocytes from G-CSF/dexamethasone treated donors in neutropenic patients with infection Blood 126(18): 2153-61, August 2015 Notes: DOI: http://dx.doi.org/10.1182/blood-2015-05-645986.

Raper, A.Kolansky, D.M.Sachais, B.S.Meagher, E.A.Bear, A.L.Cuchel, M.: Long-term clinical results of microsomaltriglyceride transfer protein inhibitor usein a patient with homozygous familialhypercholesterolemia. Journal of Clinical Lipidology 9: 107-112, 2015.

Parker Z.F., Rux A.H., Riblett A.M., Lee F.H., Rauova L., Cines D.B., Poncz M., Sachais B.S., Doms R.W.: Platelet-Factor 4 (PF4) inhibits and enhances HIV-1 infection in a concentration-dependent manner by modulating viral attachment. AIDS Res Hum Retroviruses ahead of print: doi/10.1089/AID.2015.0344, Feb 2016.